▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4141 by analyst upside · 2026-11-13
PCRX
Pacira BioSciences, Inc.
Healthcare · Market Cap $1B · P/E 39.2x
ANALYST PRICE TARGET
-7.9%
implied upside to consensus target
Current Price $36.46
Consensus Target $33.57
Bull Target $36.5
Bear Target $25.0
Analysts Covering 7
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
7
Sell
0
52-Week Low $18.8
52-Week High $36.67
YTD Return +49.1%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 39.2x
Forward P/E 10.5x
EPS (TTM) $0.93
PEG Ratio 0.99
Dividend Yield N/A
Revenue (TTM) $743M
Profit Margin 5.1%
52-WEEK RANGE
52-Week Low $18.8
52-Week High $36.67
Current Price $36.46
Bear Target $25.0
Bull Target $36.5
● Now $36.46 ● Target $33.57
TRADING DATA
Avg Volume 1.3M
YTD Return +49.1%
Analyst Count 7
Consensus Hold
Upside to Target -7.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Pacira BioSciences, Inc. (PCRX) is currently trading at $36.46 with a Wall Street consensus price target of $33.57, which is 7.9% below the current price over the next 12 months. 7 analysts currently cover PCRX, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $36.5, while the most cautious has a target of $25.0.

PCRX operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 49.1% year-to-date and is currently trading near the upper end of its 52-week range of $18.8 – $36.67.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PCRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities ↓ Downgrade
Buy → Hold 2026-10-09 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-09 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-10-09 31% win rate (48 calls)
JP Morgan ↑ Upgrade
Underweight → Neutral 2026-10-08 43% win rate (7 calls)
Jefferies ↓ Downgrade
Buy → Hold 2026-10-08 50% win rate (6 calls)
Needham ↓ Downgrade
Buy → Hold 2026-10-08 20% win rate (5 calls)
Truist Securities - Reiterated
Buy → Buy 2026-10-07 Building track record
Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
16/30
Consensus clarity
24/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →